Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Conventional induction therapy for proliferative lupus nephritis (PLN) requires high-dose glucocorticoids combined with immunosuppressants (e.g., cyclophosphamide or mycophenolate), which carries substantial risks of infections, poor adherence, and gonadotoxicity – a critical concern for reproductive-age patients. Telitacicept, a novel BLyS/APRIL dual-targeting fusion protein, may offer a safer alternative by selectively modulating B-cell pathways without broad immunosuppression, while preclinical studies indicate no adverse effects on fertility or embryo-fetal development.
A 29-year-old female developed bilateral symmetric pitting edema in the lower limbs and face for over 10 days without identifiable triggers. The edema was not accompanied by malar rash, joint pain, fever, cough, gastrointestinal symptoms, or dysuria. Serological and immunological studies revealed features consistent with systemic lupus erythematosus (SLE), and renal biopsy confirmed Class IV+V proliferative lupus nephritis according to the ISN/RPS classification, meeting the diagnostic criteria for SLE. Prior to admission, the patient received irbesartan (150 mg daily) for proteinuria management. During hospitalization, therapy was initiated with methylprednisolone (40 mg intravenously twice daily), hydroxychloroquine sulfate (200 mg orally twice daily), and telitacicept (160 mg subcutaneously weekly).
Complete clinical remission, defined as resolution of edema and normalization of urinary protein excretion, was achieved within two months without reported adverse events.
This first reported case demonstrates the feasibility of immunosuppressant-free induction therapy with telitacicept in PLN. The rapid reduction in proteinuria and absence of infections and reproductive toxicity challenge the necessity of traditional immunosuppressants, suggesting a paradigm shift toward targeted biologic therapies. Further studies are warranted to validate this approach.
